<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Genetic causes of focal segmental glomerulosclerosis (FSGS)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Genetic causes of focal segmental glomerulosclerosis (FSGS)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Genetic causes of focal segmental glomerulosclerosis (FSGS)</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="15%"></colgroup><colgroup span="2" width="20%"></colgroup><colgroup width="10%"></colgroup><colgroup width="20%"></colgroup> <tbody> <tr> <td class="subtitle1">Gene locus</td> <td class="subtitle1">Protein</td> <td class="subtitle1">Protein function</td> <td class="subtitle1">Phenotype</td> <td class="subtitle1">Inheritance</td> <td class="subtitle1">Response to therapy</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Slit diaphragm associated proteins</td> </tr> <tr> <td class="indent1"><em>NPHS1</em><br/> 19q13.1</td> <td>Nephrin</td> <td> <p>Member of the immunoglobulin family</p> Essential component of the slit diaphragm</td> <td>Finnish type congenital nephrotic syndrome, sporadic childhood FSGS, rarely adult onset FSGS</td> <td class="centered">AR</td> <td>Resistant to immunosuppression, reported cases of response to immunosuppression in heterozygous mutations or variants</td> </tr> <tr> <td class="indent1"><em>NPHS2</em><br/> 1q25.2</td> <td>Podocin</td> <td>Transmembrane protein involved in recruitment of nephrin to the slit diaphragm</td> <td>Familial or sporadic FSGS or DMS in early childhood-, adolescence-, or adult-onset FSGS in particular in compound heterozygotes for one pathogenic <em>NPHS2</em> mutation and p.R229Q polymorphism</td> <td class="centered">AR</td> <td>Resistant to immunosuppression, reported cases of response to immunosuppression in heterozygous mutations or variants</td> </tr> <tr> <td class="indent1"><em>CD2AP</em><br/> 6p12</td> <td>CD2-associated protein</td> <td>Scaffolding molecule between slit diaphragm and actin cytoskeleton</td> <td>Childhood-onset FSGS</td> <td class="centered">AD, rarely AR</td> <td>Resistant to immunosuppression</td> </tr> <tr> <td class="indent1"><em>PLCE1</em><br/> 10q23.33</td> <td>Phospholipase C epsilon 1</td> <td>Signaling protein, interacts with nephrin</td> <td>Isolated DMS, sporadic and familial early childhood-onset FSGS</td> <td class="centered">AR</td> <td>Reported cases of (partial) response to immunosuppression</td> </tr> <tr> <td class="indent1"><em>TRPC6</em><br/> 11q22.1</td> <td>Transient receptor potential cation channel 6</td> <td>Receptor-activated calcium channel localized at the foot process membrane, interacts with nephrin and podocin</td> <td>Familial or sporadic adult-onset FSGS, childhood-onset FSGS has also been described</td> <td class="centered">AD</td> <td>Reported cases of (partial) response to immunosuppression</td> </tr> <tr> <td class="indent1"><em>MAGI2</em><br/> 7q11.23-q21.11</td> <td>Membrane-associated guanylate kinase, WW, and PDZ domain-containing 2</td> <td>Scaffolding molecule between slit diaphragm and actin cytoskeleton</td> <td>Familial and sporadic congenital nephrotic syndrome</td> <td class="centered">AR</td> <td>Resistant to immunosuppression</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Actin cytoskeleton and regulation</td> </tr> <tr> <td class="indent1"><em>ACTN4</em><br/> 19q13</td> <td>Alpha-actinin-4</td> <td>Member of the spectrin gene superfamily, cytoskeletal protein</td> <td>Familial or sporadic adult-onset FSGS</td> <td class="centered">AD</td> <td>Resistant to immunosuppression</td> </tr> <tr> <td class="indent1"><em>MYO1E</em><br/> 15q22.2</td> <td>Nonmuscle myosin 1e</td> <td> <p>Member of the nonmuscle class I myosins</p> Involved in intracellular movement and membrane trafficking</td> <td>Familial childhood-onset FSGS</td> <td class="centered">AR</td> <td>Reported cases of (partial) response to cyclosporine</td> </tr> <tr> <td class="indent1"><em>ANLN</em><br/> 7p15-p14</td> <td>Anillin</td> <td>F-actin binding protein, involved in slit diaphragm-cytoskeleton binding</td> <td>Familial adult-onset FSGS</td> <td class="centered">AD</td> <td>Resistant to immunosuppression</td> </tr> <tr> <td class="indent1"><em>ARHGDIA</em><br/> 17q25.3</td> <td>Rho GDP dissociation inhibitor alpha</td> <td>Regulation of podocyte migratory phenotype and shape</td> <td>Congenital or early childhood-onset nephrotic syndrome</td> <td class="centered">AR</td> <td>Resistant to immunosuppression, may respond to RAC1 inhibitors (eplerenone)</td> </tr> <tr> <td class="indent1"><em>ARHGAP24</em><br/> 4q22.1</td> <td>Rho GTPase activating protein 24</td> <td>Regulation of podocyte migratory phenotype and shape</td> <td>Adolescence-onset FSGS</td> <td class="centered">AD</td> <td>Resistant to immunosuppression</td> </tr> <tr> <td class="indent1"><em>TTC21B</em><br/> 2q24.3</td> <td>Tetratricopeptide repeat domain 21B</td> <td>Intraflagellar transport-A component, regulation cytoskeleton adult podocytes</td> <td>Adolescence- or adult-onset FSGS associated with atrophic tubules</td> <td class="centered">AR</td> <td>Resistant to immunosuppression</td> </tr> <tr> <td class="indent1"><em>KANK2</em><br/> 19p13.2</td> <td>Kidney ankyrin repeat-containing protein 2</td> <td>Regulation Rho GTPase activity in podocytes (cell migration and shape)</td> <td>Familial early-onset SRNS</td> <td class="centered">AR</td> <td>Resistant to immunosuppression</td> </tr> <tr> <td class="indent1"><em>INF2</em><br/> 14q32.33</td> <td>Inverted formin 2</td> <td>Member of the formin family, function in depolymerization and polymerization of actin filaments</td> <td>Familial or sporadic adolescence- and adult-onset FSGS</td> <td class="centered">AD</td> <td>Resistant to immunosuppression</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Nuclear pore complex proteins</td> </tr> <tr> <td class="indent1"><em>NUP93</em><br/> 16q13</td> <td>Nucleoporine 93 kDa</td> <td>Component of the nuclear pore complex</td> <td>Familial childhood-onset SRNS</td> <td class="centered">AR</td> <td>Resistant to immunosuppression</td> </tr> <tr> <td class="indent1"><em>NUP205</em><br/> 7q33</td> <td>Nucleoporine 205 kDa</td> <td>Component of the nuclear pore complex</td> <td>Familial childhood-onset SRNS</td> <td class="centered">AR</td> <td>Resistant to immunosuppression</td> </tr> <tr> <td class="indent1"><em>XPO5</em><br/> 6p21.1</td> <td>Exportin 5</td> <td>Component of the nuclear pore complex</td> <td>Familial childhood-onset SRNS</td> <td class="centered">AR</td> <td>Resistant to immunosuppression</td> </tr> <tr> <td class="indent1"><em>NUP107</em><br/> 12q15</td> <td>Nucleoporine 107 kDa</td> <td>Component of the nuclear pore complex</td> <td>Childhood-onset FSGS</td> <td class="centered">AR</td> <td>Resistant to immunosuppression</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Cell membrane-associated proteins</td> </tr> <tr> <td class="indent1"><em>PTPRO</em><br/> 12p13-p12</td> <td>Protein tyrosine phosphatase, receptor type O</td> <td>Member of the R3 subtype family of protein tyrosine phosphatases at the apical surface of polarized cells</td> <td>Childhood-onset FSGS</td> <td class="centered">AR</td> <td>Resistant to immunosuppression, reported cases of (partial) response to immunosuppression</td> </tr> <tr> <td class="indent1"><em>EMP2</em><br/> 16p13.2</td> <td>Epithelial membrane protein 2</td> <td>Regulation of the amount of CAVEOLIN-1, EMP2 depletion causes decreased cell proliferation</td> <td>Childhood-onset FSGS</td> <td class="centered">AR</td> <td>Reported cases of response to steroids</td> </tr> <tr> <td class="indent1"><em>PODXL</em><br/> 7q32.3</td> <td>Podocalyxin</td> <td>Component of glycocalyx</td> <td>Familial childhood- and adult-onset FSGS</td> <td class="centered">AD</td> <td>Resistant to immunosuppression</td> </tr> <tr> <td class="subtitle2_left" colspan="6">GBM protein</td> </tr> <tr> <td class="indent1"><em>LAMA5</em><br/> 20q13.2-q13.3</td> <td>Laminin alpha-5</td> <td>Member of the alpha-subfamily of laminin chains, major component of basement membranes</td> <td>Adult-onset FSGS</td> <td class="centered">AR/AD</td> <td>Likely resistant to immunosuppression</td> </tr> </tbody></table></div><div class="graphic_footnotes">AD: autosomal dominant; AR: autosomal recessive; DMS: diffuse mesangial sclerosis; FSGS: focal segmental glomerulosclerosis; GBM: glomerular basement membrane; GDP: guanosine diphosphate; GTP: guanosine triphosphate; kDA: kilodalton; SRNS: steroid-resistant nephrotic syndrome.</div><div class="graphic_reference">Adapted with permission from: De Vriese AS, Sethi S, Nath KA, et al. Differentiating primary, genetic, and secondary FSGS in adults: A clinicopathologic approach. J Am Soc Nephrol 2018; 29:759. Copyright Â© 2018 American Society of Nephrology.</div><div id="graphicVersion">Graphic 118938 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
